Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises Additional $9M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Direct-to-consumer genomics firm 23andMe today announced it has raised an additional $9 million in its Series C financing round, bringing the total funding in the round to $31 million.

MPM Capital joined Johnson & Johnson Development Corp. as a new investor, the Mountain View, Calif.-based firm said. Ashley Ledbetter Dombkowski, a director at MPM, is joining 23andMe's board, it added.

In November, the company said it had raised $22 million in the round. The funding will be used to accelerate the firm's research, it added.

Along with MPM and J&J, other investors in 23andMe include Roche Venture Fund, Google Ventures, and New Enterprise Associates.

In a statement, 23andMe CEO Anne Wojcicki said the firm "has aligned a powerful constellation of expertise in strategic healthcare, healthcare venture funding, consumer markets, information technology, and business strategy that will enable us to bring the vision of personalized medicine to consumers faster."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.